VIRIDIAN THERAPEUTICS, INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2007-01-01
- Employees
- 96
- Market Cap
- -
Clinical Trials
11
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials
A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)
- Conditions
- Thyroid Eye Disease
- Interventions
- Device: Autoinjector
- First Posted Date
- 2025-09-04
- Last Posted Date
- 2025-09-04
- Lead Sponsor
- Viridian Therapeutics, Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT07155668
- Locations
- 🇺🇸
United Medical Research Institute, Inglewood, California, United States
🇺🇸Ilumina Medical Research, Kissimmee, Florida, United States
🇺🇸Hype Clinical Research, LLC, Miami, Florida, United States
A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)
- First Posted Date
- 2025-02-06
- Last Posted Date
- 2025-08-14
- Lead Sponsor
- Viridian Therapeutics, Inc.
- Target Recruit Count
- 284
- Registration Number
- NCT06812325
- Locations
- 🇺🇸
Catalina Eye Care, Tuscon, Arizona, United States
🇺🇸United Medical Research Institute, Inglewood, California, United States
🇺🇸Orbital Plastics, Newport Beach, California, United States
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)
- First Posted Date
- 2024-10-03
- Last Posted Date
- 2025-09-30
- Lead Sponsor
- Viridian Therapeutics, Inc.
- Target Recruit Count
- 117
- Registration Number
- NCT06625411
- Locations
- 🇺🇸
Scottsdale Clinical Trials, Scottsdale, Arizona, United States
🇺🇸Alliance Research Institute - Canoga Park, Canoga Park, California, United States
🇺🇸Marvel Clinical Research, Huntington Beach, California, United States
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)
- First Posted Date
- 2024-10-03
- Last Posted Date
- 2025-09-30
- Lead Sponsor
- Viridian Therapeutics, Inc.
- Target Recruit Count
- 195
- Registration Number
- NCT06625398
- Locations
- 🇺🇸
Scottsdale Clinical Trials, Scottsdale, Arizona, United States
🇺🇸Alliance Research Institute - Canoga Park, Canoga Park, California, United States
🇺🇸Marvel Clinical Research, Huntington Beach, California, United States
A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED)
- Conditions
- Thyroid eye disease
- First Posted Date
- 2024-04-25
- Last Posted Date
- 2025-07-04
- Lead Sponsor
- Viridian Therapeutics Inc.
- Target Recruit Count
- 155
- Registration Number
- 2023-507563-19-00
- Locations
- 🇳🇱
Stichting Amsterdam UMC, Amsterdam, Netherlands
🇵🇱4 Wojskowy Szpital Kliniczny Z Poliklinika Samodzielny Publiczny Zaklad Opieki Zdrowotnej We Wroclawiu, Wroclaw, Poland
🇵🇱Santa Sp. z o.o., Lodz, Poland
- Prev
- 1
- 2
- Next